# Talus Bio

> Talus Bio is a Seattle drug-discovery company going after transcription factors and other regulatory proteins long written off as 'undruggable.' Its MARMOT platform measures the human regulome directly in living cells using functional proteomics and high-throughput mass spectrometry, then feeds tens of millions of compound-target interactions into a lab-in-the-loop AI system to design small molecules that switch disease-driving genes on or off. Founded in 2020 by Alex Federation and Lindsay Pino, the company runs preclinical programs in chordoma, non-small cell lung cancer, and prostate cancer.

- **Founded:** 2020
- **Headquarters:** Seattle, Washington, United States
- **Founders:** Alex Federation (Co-Founder & CEO), Lindsay Pino (Co-Founder & CTO)
- **Team size:** ~26 employees
- **Products:** MARMOT Platform, Native Regulome Profiling, Lab-in-the-loop AI, Transcription Factor Therapeutic Programs, Tech Access Program
- **Notable:** Invented MARMOT, a platform to profile the regulome in native living cells, Raised $24.71M total including an $11.2M round led by Two Bear Capital (2024), Secured $4.3M in non-dilutive grant funding for the discovery platform

## Products & services

- **MARMOT Platform** — Multiplexed Assays for the Rational Modulation Of Transcription Factors - a discovery platform integrating AI, next-generation functional proteomics, synthetic chemistry, and computational biology to profile and modulate regulome activity in living cells.
- **Native Regulome Profiling** — Functional proteomics and high-throughput mass spectrometry that quantify thousands of regulome targets - transcription factors and DNA regulators - directly in native human cells.
- **Lab-in-the-loop AI** — Foundation AI models trained on tens of millions of compound-target interactions generated monthly, used to design and optimize small molecules that alter regulome activity.
- **Transcription Factor Therapeutic Programs** — Preclinical small-molecule programs targeting transcription factors in chordoma (brachyury), non-small cell lung cancer, and advanced prostate cancer.
- **Tech Access Program** — A program opening Talus's regulome-profiling technology to outside academic and industry labs to help chart the human regulome.

## Achievements

- Invented MARMOT, a platform to profile the regulome in native living cells
- Raised $24.71M total including an $11.2M round led by Two Bear Capital (2024)
- Secured $4.3M in non-dilutive grant funding for the discovery platform
- Presented preclinical transcription-factor program data at AACR 2025
- Launched a Tech Access Program to open its regulome technology to outside labs
- Signed a 2025 discovery collaboration with PRISM BioLab
- Generates tens of millions of compound-target interactions per month

## Latest updates

- **2025-12** — Announced collaboration with PRISM BioLab to discover novel modulators of transcription factor and protein-protein interaction targets.
- **2025-04** — Presented preclinical data on transcription factor therapeutic programs at AACR 2025.
- **2025** — Launched Tech Access Program to help chart the human regulome with outside labs.
- **2024-08** — Announced $11.2M in new funding led by Two Bear Capital to advance its AI platform for transcription-factor therapeutic discovery.

## Links

- Website: https://talus.bio
- LinkedIn: https://www.linkedin.com/company/talus-bio
- Twitter/X: https://twitter.com/talusbio

---

Profile page: https://yespress.io/talus-bio
Published by YesPress — https://yespress.io
Last updated: 2026-07-02